← All trials
NCT04183725
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2019
- Primary completion
- Jun 1, 2021
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- Shanxi College of Traditional Chinese MedicineCollaborator
- China Academy of Chinese Medical SciencesStudy chair
- Soochow UniversityCollaborator
- Wuhan UniversityCollaborator
- China Academy of Chinese Medical SciencesReponsible party - principal investigator
- Anhui Medical UniversityCollaborator
- The Fourth Central Hospital of TianjinCollaborator
- Hunan University of Traditional Chinese MedicineCollaborator
- Nanchang UniversityCollaborator
- Shandong UniversityCollaborator
- Southern Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.